AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 271 min read$IQV

IQVIA signals 2026 revenue of $17.350B-$17.500B and adjusted EPS of $12.90-$13.00 as clinical bookings reach $11.7B on an LTM basis (NYSE:IQV)

IQVIA Holdings Inc. projected 2026 revenue of $17.35B-$17.5B and adjusted EPS of $12.90-$13.00, with clinical bookings reaching $11.7B on an LTM basis, according to the company.

Original reporting
seekingalpha.com
Published Oct 27, 2026, 4:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 4:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IQVIA signals 2026 revenue of $17.350B-$17.500B and adjusted EPS of $12.90-$13.00 as clinical bookings reach $11.7B on an LTM basis (NYSE:IQV) — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$IQVNeutralHigh
01

Why it matters

The guidance sets expectations for revenue growth and profitability through 2026, influencing investor sentiment and valuation models.

02

Market read

First‑time release of multi‑year guidance for a large-cap healthcare services firm.

03

What to watch

Potential impact of upcoming regulatory changes or macro‑economic headwinds on future contracts.

Relevance 9/10Novelty 9/10Timing: today

Background

IQVIA is a leading provider of data, technology, and services to the life sciences industry.

Company-level read

Ticker impact

$IQVNeutralHigh confidence
Context

IQVIA disclosed 2026 revenue guidance of $17.35B‑$17.50B and adjusted EPS of $12.90‑$13.00, the first public release of these figures.

Expected impact

potential upward pressure if market views guidance as a beat, otherwise modest downside risk

Evidence & confidence

New, material guidance for a large-cap company provides a clear trading catalyst.

Market effects

Sector

Positive guidance may boost the broader healthcare services sector.

Regional

U.S. market participants may adjust exposure to contract research organizations.

Global

Limited to markets tracking U.S. healthcare stocks.

Counterpoint

What could challenge this read

If guidance falls short of analyst consensus, the stock could face a sell‑off despite the numbers.

Key entities

  • Company
    IQVIA Holdings Inc.

    Provider of healthcare data and analytics.

Read at source← All news

StoryIQVIA reports Q3 2026 beat and lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 28
$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com2 min
OCT 27
$IQVHighAI 8/10

IQVIA Holdings Inc. Q3 2026 Earnings Call Summary

IQVIA Holdings Inc. reported Q3 2026 organic revenue growth of 6%, driven by clinical segment momentum and AI integration. The Emerging Biopharma segment saw record demand with $90B funding YTD. Full-year guidance was raised, with AI expected to support future margin expansion. Management highlighted competitive advantages through AI and strategic partnerships. Q4 interest expense is projected at $210M. A $2.1B backlog scrub was conducted to improve visibility.

finance.yahoo.com3 min